TWILIGHT-HF Subgroup Analysis Score
- Exploratory TWILIGHT-HF Subgroup Analysis Score: Explanation and context
The TWILIGHT randomized trial tested whether, among high-risk patients who had completed 3 months of dual antiplatelet therapy after PCI, stopping aspirin and continuing ticagrelor monotherapy reduced clinically relevant bleeding without increasing ischemic events. The trial found a lower rate of BARC 2/3/5 bleeding with ticagrelor monotherapy versus ticagrelor plus aspirin, with ischemic outcomes noninferior across the whole study population. Subgroup analyses (preplanned and post-hoc) assessed consistency of the bleeding/ischemic effects across groups defined by age, sex, diabetes, ACS status and other baseline variables. This tool aggregates a small set of those subgroup variables into a transparent point count to illustrate relative subgroup burden; it is not a replication of a published predictive score and does not produce validated absolute risk predictions.
Reference:
Mehran R, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019;381:1309–1320.
Additional prespecified and subgroup analyses and commentaries: sex and subgroup analyses (see listed publications and meeting presentations).
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.